{"entity":{"id":"pathios-therapeutics","kind":"company","name":"Pathios Therapeutics","aka":["Pathios Therapeutics Ltd"],"tldr":"Pathios Therapeutics makes PTT-4256, a tablet designed to stop the acidic surroundings of a tumour from switching off the immune cells inside it. It is in an early trial in people with advanced solid tumours.","summary":"Pathios Therapeutics Ltd is an Oxford, UK, drug discovery company established in 2017, according to the company. It targets GPR65, an acid-sensing G protein-coupled receptor on immune cells; the company's case is that the low pH of solid tumours signals through GPR65 to push T cells, NK cells, dendritic cells and especially macrophages towards an immunosuppressed, pro-tumour state. Its lead asset PTT-4256 is an orally bioavailable, selective GPR65 inhibitor. The company says it has raised a total of $58 million in venture funding, most recently a Series B to take PTT-4256 into the clinic. Its first registered cancer trial, NCT06634849 (RAISIC-1), a modular phase 1/2 dose-finding study of once-daily oral PTT-4256 in solid tumours at Australian sites, sponsored by its Australian subsidiary Pathios Therapeutics Pty Ltd, was posted on ClinicalTrials.gov in October 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://pathios.com/"},{"label":"About Pathios","url":"https://pathios.com/about-us/"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06634849"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["OnCo has no target record for GPR65 and no technology record for GPCR-directed small molecules, so neither is linked.","Investor names on the company's investors page are shown as logos and were not read.","Company website read on 29 October 2026."],"hq":"Oxford","country":"GB","companyType":"biotech","website":"https://pathios.com/","founded":2017,"stage":"growth","investors":[],"funding":[{"round":"Venture total","year":2024,"amountUsd":58000000,"source":"https://pathios.com/about-us/","note":"Total venture funding to date as stated on the company's About page, including a Series B; the year is when the trial began and is approximate, as the page does not date the Series B."}]},"route":"/companies/pathios-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"trial":[{"id":"nct06634849","kind":"trial","name":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).","route":"/trials/nct06634849/"}]}}